The Institute for Biomolecular Targeting - Equipment Supplement 2022

生物分子靶向研究所 - 设备补充材料 2022

基本信息

批准号：
10581943
负责人：
DEAN R MADDEN
金额：
$ 23万
依托单位：
DARTMOUTH COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-15 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10581943
关键词：
2019-nCoV Address Antibodies Area Autophagocytosis Award Awareness Binding Biological Businesses Career Mobility Centers of Research Excellence Communities Complex Consult Consultations Core Facility Cryoelectron Microscopy Cystic Fibrosis Development Diabetes Mellitus Disease Drug Targeting Equipment Extramural Activities Faculty Faculty Recruitment Financial Support Fostering Foundations Funding Future Generations Goals Grant Home Image Immunologics Infection Infrastructure Institutes Investigation Investments Ion Channel Malignant Neoplasms Mass Spectrum Analysis Membrane Fusion Mentors Metabolic Control Microscope Microscopy Modeling Molecular Molecular Target Neoplasm Metastasis Pathology Phase Play Postdoctoral Fellow Production Productivity Program Reviews Protein Biochemistry Proteins Recovery Research Research Institute Research Personnel Research Project Grants Resources Respiratory Tract Infections Role Schools Scientist Seasons Series Services Signal Transduction Subgroup Targeted Research Teacher Professional Development Technology Testing Therapeutic Time Translations Vaccines Virus Diseases Work base career clinical practice cohort community building cost diversity and inclusion drug development experience faculty research faculty support fascinate forging fundamental research innovation instrument instrumentation interest knowledge translation member mid-career faculty molecular imaging new technology novel therapeutic intervention operation pre-clinical preclinical development programs protein expression recruit success symposium therapeutic target tool translational goal tumor progression

项目摘要

The Dartmouth Institute for Biomolecular Targeting (bioMT) infuses mechanistic investigations with a sophisticated awareness of disease pathology and therapeutic need, enhancing the quality of even the most fundamental research. At the same time, it helps orient mechanistic investigations towards long-term translational goals for complex diseases such as cancer and infections. In phase I, our progress was strong. All six of our research project leaders (RPL) with more than two years’ support have received R01-equivalent funding. Our cores provide unique protein biochemistry resources and ‘navigators’ to access microscopes campus-wide. Our cores and seminars have created a vibrant and interdisciplinary community. Here, we propose to deploy phase II COBRE and institutional program enrichment funds to build on this foundation and fill key gaps to prepare bioMT for the transition to sustainable COBRE independence. Aim 1 is to increase our cohort of funded bioMT investigators to fill strategic roles in our research landscape. Our two most recent RPLs (3–15 months’ support) are continuing into phase II, joined by two outstanding new hires. Their projects explore basic signaling and immunological mechanisms with potential relevance to therapeutic targets ranging from respiratory infections to cancer progression and metastasis, interconnected by shared scientific and technical interests. All receive guidance from dedicated mentoring dyads to assist in career advancement and independent extramural funding, and all receive support from responsive scientific cores offering state-of-the- art technologies directly relevant to their bioMT research projects. With institutional support, we will also hire five new faculty members, aligned with our theme of discovering and exploiting molecular targets, and selected to enhance thematic subgroups. As starting RPLs graduate, we will recruit new hires and other potential candidates for EAC consideration as replacements. Aim 2 is to enhance our core facilities and prepare them for a transition to COBRE independence during phase III. The cores are fully staffed and have invested heavily in phase I instrumentation. We will partner to add key new technologies based on user input, including parallel protein expression, mass spectrometry, advanced microscopy, and cryoEM. Cost-recovery models will be developed for incremental deployment in phase III to enable core financial independence. Aim 3 continues enriching our community, including mini-symposia and pilot awards to foster new multi-PI and program-project applications, which will contribute to core sustainability. Overall, these aims will leverage proven COBRE strategies – junior faculty hiring, extramural and academic mentoring, excellent administrative and scientific core support, and interdisciplinary community building – to enhance bioMT’s scientific impact in targeted areas of need. This will prepare us for the transition to phase III funding and ultimate independence as an interdisciplinary and nationally visible research institute, spanning three schools and 10 departments at Dartmouth and deeply connected to local centers and regional IDeA partners.

达特茅斯生物分子靶向研究所 (bioMT) 将机械研究与对疾病病理学和治疗需求的深入认识，提高即使是最同时，它有助于将机械研究导向长期。在第一阶段，我们的进展强劲。我们所有六位获得两年以上支持的研究项目负责人 (RPL) 均已获得 R01 同等资格我们的核心提供独特的蛋白质生物化学资源和访问显微镜的“导航器”。我们的核心和研讨会在这里创建了一个充满活力的跨学科社区。建议在此基础上部署第二阶段 COBRE 和机构计划充实基金填补关键空白，为 bioMT 向可持续 COBRE 过渡做好准备目标 1 是增强我们的能力。一批受资助的 BioMT 研究人员在我们最近的两个研究领域中担任战略角色。 RPL（3-15 个月的支持）正在继续进入第二阶段，两名杰出的新员工也加入了他们的项目。探索与治疗靶点潜在相关的基本信号传导和免疫机制从呼吸道感染到癌症进展和转移，通过共同的科学和技术相互关联所有人都接受专门的指导二人组的指导，以协助职业发展和独立的外部资金，并且都得到响应迅速的科学核心的支持，提供最先进的在机构支持下，我们还将聘请与他们的生物机器翻译研究项目直接相关的艺术技术。五名新的教职人员，与我们发现和利用分子靶标的主题相一致，以及选择增强主题小组随着 RPL 毕业生的毕业，我们将招募新员工和其他人员。目标 2 是增强我们的核心设施和能力。为第三阶段过渡到 COBRE 独立性做好准备。核心人员配备齐全，并拥有充足的人员。我们将在第一阶段仪器上投入大量资金，根据用户的意见添加关键的新技术，包括平行蛋白质表达、质谱、先进显微镜和冷冻电镜。将开发第三阶段增量部署模型，以实现核心财务独立。 3 继续丰富我们的社区，包括小型研讨会和试点奖项，以培养新的多 PI 和总体而言，这些目标将有助于实现核心可持续性。行之有效的 COBRE 策略 – 初级教师招聘、校外和学术指导、优秀的行政管理和科学核心支持，以及跨学科社区建设——以增强bioMT在以下领域的科学影响力：这将为我们过渡到第三阶段融资和最终独立做好准备。作为一个跨学科、全国知名的研究机构，涵盖三个学院和 10 个系达特茅斯学院与当地中心和地区 IDeA 合作伙伴有着密切的联系。